Skip to main content

Day: April 24, 2020

Verizon begins 2020 with strong earnings and cash flow from focused strategic execution

1Q 2020 highlightsConsolidated:$1.00 in earnings per share (EPS), compared with $1.22 in 1Q 2019; adjusted EPS (non-GAAP), excluding special items, of $1.26, compared with $1.20 in 1Q 2019.Operating revenue decline of 1.6 percent from first-quarter 2019.Cash flow from operations of $8.8 billion, an increase of $1.7 billion from first-quarter 2019.Consumer:Total revenue of $21.8 billion, a decrease of 1.7 percent year over year.525,000 retail postpaid net losses, including 307,000 phone net losses and 167,000 postpaid smartphone net losses.Total retail postpaid churn of 1.01 percent, and retail postpaid phone churn of 0.77 percent.59,000 Fios Internet net additions.Business:Total revenue of $7.7 billion, a decrease of 0.5 percent year over year.475,000 retail postpaid net additions, including 239,000 phone net additions.Total retail postpaid...

Continue reading

Era Group Repurchases Under the Previously Announced Special Stock Repurchase Program

HOUSTON, April 24, 2020 (GLOBE NEWSWIRE) — Era Group Inc. (NYSE:ERA) (“Era”) announced today that on April 21, 2020 it repurchased an aggregate of 54,099 shares of its common stock at an average price of $3.64 per share, on April 22, 2020 it repurchased an aggregate of 46,027 shares of its common stock at an average price of $3.81 per share and on April 23, 2020 it repurchased an aggregate of 24,036 shares of its common stock at an average price of $4.23 per share under its previously announced special stock repurchase program, which allows for the purchase of up to $10 million of its common stock (the “Program”). All shares of common stock repurchased under the Program will be held as treasury shares. Following the repurchase of shares under the Program to date, Era will have 21,632,110 shares of common stock outstanding.The total...

Continue reading

Colony Bankcorp Reports First Quarter 2020 Results

FITZGERALD, Ga., April 24, 2020 (GLOBE NEWSWIRE) — Colony Bankcorp, Inc. (Nasdaq: CBAN) (“Colony” or the “Company”) today reported net income of $1.6 million or $0.17 per diluted share for the first quarter of 2020 compared to $2.8 million or $0.34 per diluted share for the same period in 2019. The Company reported operating net income (a non‑GAAP financial measure) of $1.9 million or $0.17 per diluted share in the first quarter of 2020 versus $2.9 million or $0.34 per diluted share for the same period prior year. Operating net income excludes charges for acquisition-related expenses as well as gains on the sales of other real estate owned (“OREO”). See the reconciliation of non-GAAP financial measures included below.Separately, the Company also announced that on April 22, 2020, the Board of Directors declared a quarterly cash dividend...

Continue reading

Credicorp Announces Decisions Related to the Annual General Shareholders Meeting

Lima, April 24, 2020 (GLOBE NEWSWIRE) — Lima, April 23, 2020 – Credicorp Ltd. announces that the Board of Directors, in its session held on April 23rd, 2020, has agreed to schedule the Annual General Shareholders Meeting to take place on June 5th, 2020 at 3:00 pm. In order to protect the health and safety of our employees, shareholders and other stakeholders from the COVID-19 pandemic, Credicorp will hold the meeting virtually and there will be no in-person meeting this year. Shareholders registered as of May 6th will have the right to attend and vote at the meeting. Details of virtual meeting logistics will be provided shortly along with the Annual General Shareholders Meeting Notice.Credicorp postponed its Annual General Shareholders Meeting, originally scheduled to take place on March 27th, 2020, in order to prevent the transmission...

Continue reading

Ændring af bestyrelsens forslag til generalforsamling

Selskabsmeddelelse nr. 26/2020| 24. april 2020Danske Andelskassers Bank A/S har i selskabsmeddelelse nr. 20/2020 den 6. april 2020 udsendt indkaldelse til generalforsamling den 29. april 2020.Under dagsordenens pkt. 8 b) stiller bestyrelsen forslag om en bemyndigelse til forhøjelse af bankens aktiekapital uden fortegningsret for de hidtidige aktionærer. Forslaget fastholdes, men bestyrelsen har besluttet at nedsætte størrelsen af bemyndigelsen, således at der alene anmodes om en bemyndigelse til at forhøje bankens aktiekapital med op til i alt nominelt kr. 74.364.924 svarende til 20% af bankens aktiekapital.Den fulde ordlyd af forslaget under dagsordenens pkt. 8 b) er herefter: Ad pkt. 8 b) Ændring af § 4a, stk. 2Bestyrelsen stiller forslag til ændring af bankens vedtægter, hvorved der indsættes en bemyndigelse til bestyrelsen til at gennemføre...

Continue reading

Algernon的艾芬地尔第二阶段新冠肺炎人类研究在韩国获得监管和伦理审批

不列颠哥伦比亚省温哥华, April 24, 2020 (GLOBE NEWSWIRE) — 临床阶段药物开发企业Algernon Pharmaceuticals Inc.(CSE: AGN)(FRANKFURT: AGW)(OTCQB: AGNPF)(以下称“该公司”或“Algernon”)非常高兴地宣布,其再利用药物NP-120(艾芬地尔)(NMDA受体拮抗剂)的研究者主导的第二阶段新冠肺炎临床研究已获得韩国食品和药物安全部的批准,并已通过伦理审查。首席研究员是釜山市东亚大学医院传染病科教授Dong Sik Jung博士。此次对40名患者进行的为期4周的试验旨在测试艾芬地尔对出现严重肺炎症状的新冠病毒感染者的治疗效果。患者按1:1的比例随机分组,分别接受标准疗法(SOC)和采用艾芬地尔的SOC。主要测试指标将是通过测量血液含氧量(Pa02/Fi02)获知患者肺部功能提升的速度。次要测试指标包括死亡率、呼吸机使用率,以及患者反馈的针对咳嗽和呼吸困难症状的效果。参与第2阶段临床试验的注册预计将于2020年5月8日开始。“艾芬地尔用于新冠肺炎患者的首次人类试验是我们新的急性肺部损伤临床研究计划向前迈出的一大步”,Algernon首席执行官Christopher J. Moreau表示。“随着我们继续研究艾芬地尔针对新冠肺炎的治疗潜力,第2阶段的肯定性数据将是一个重要的里程碑;此外,这也将推进我们的特发性肺纤维化和慢性咳嗽研究计划。”该公司提示,虽然公司正准备于近期在韩国开始第二阶段临床试验,但并没有对NP-120(艾芬地尔)作为急性肺部损伤(ALI)、新冠肺炎病毒或任何其他疾病的有效疗法做出任何明示或暗示的声明。关于NP-120(艾芬地尔)NP-120(艾芬地尔)是一种N-甲基-d-天冬氨酸(NDMA)受体拮抗剂,专门针对NMDA型亚基2B(Glu2NB)。艾芬地尔可阻止谷氨酸信号传导。肺部细胞和T细胞、中性粒细胞等许多组织中都有NMDA受体。该公司认为NP-120可以减少中性粒细胞和T细胞浸润到肺中,而这两种细胞在肺部可分别释放谷氨酸和细胞因子。后者可能导致非常严重的细胞因子风暴,致使肺部功能丧失,并最终导致死亡,正如报告的新冠病毒感染者所出现的情况。关于Algernon...

Continue reading

Algernon 獲得在韓國進行第 2 期 Ifenprodil 的 COVID-19 人類研究的監管和倫理批准

卑詩省溫哥華, April 24, 2020 (GLOBE NEWSWIRE) — Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF)(下稱「公司」或「Algernon」)是一家臨床階段的藥物開發公司,現欣然宣佈已獲得韓國食品和藥物安全部的批准,並已獲得倫理機構批准進行研究人員主導的 NP-120 (Ifenprodil) 第 2 期 2019 冠狀病毒病 (COVID-19) 臨床研究。Ifenprodil 是一種 NMDA 受體拮抗劑及公司的重新定位藥物。首席研究員是釜山東亞大學附屬醫院傳染病科醫生 Dong Sik Jung 教授。這項為期 4 週、涉及 40 名患者的試驗旨在測試 Ifenprodil 在感染 COVID-19 的嚴重肺炎患者中的作用。將患者以 1:1 的方式隨機分配,以接受標準護理或 Ifenprodil 標準護理。主要終點是透過測量血液中的氧氣水平 (Pa02/Fi02) 瞭解改善肺功能的速率。次要終點包括死亡率、機械通風率及患者報告的咳嗽和呼吸困難造成的影響。預計將於 2020 年 5 月 8 日開始就第 2 期臨床試驗招募受試者。Algernon 行政總裁 Christopher J. Moreau 表示:「Ifenprodil 在 COVID-19 患者中的首次人類試驗是我們新的急性肺損傷臨床研究計劃的重要一步。第 2 期的正面數據將是一個重要的里程碑,因為我們除了繼續推進特發性肺纖維化和慢性咳嗽計劃外,還將繼續研究 Ifenprodil 作為 COVID-19 治療的潛力。」公司十分謹慎,儘管正為韓國即將開始的第 2 期臨床試驗做準備,但此舉並不明確或暗示聲稱 NP-120 (Ifenprodil) 可有效治療急性肺損傷、COVID-19 病毒或現時的任何其他醫療狀況。關於 NP-120 (Ifenprodil)NP-120...

Continue reading

Algernon reçoit une approbation réglementaire et éthique pour l’étude humaine de phase 2 sur l’ifenprodil dans le cadre du traitement du COVID-19 en Corée du Sud

VANCOUVER, Colombie-Britannique, 24 avr. 2020 (GLOBE NEWSWIRE) — Algernon Pharmaceuticals Inc. (CSE : AGN) (FRANCFORT : AGW) (OTCQB : AGNPF) (la « Société » ou « Algernon »), société de développement pharmaceutique au stade clinique, a le plaisir d’annoncer qu’elle a reçu l’approbation du ministère de la sécurité sanitaire des aliments et des médicaments en Corée du Sud, ainsi que l’approbation d’éthique, pour une étude clinique de phase 2 menée par des chercheurs sur le COVID-19 pour son médicament reconverti NP-120 (ifenprodil), un antagoniste des récepteurs NMDA.Le chercheur principal est le Dr Dong Sik Jung, professeur, dans la division des maladies infectieuses du Dong-A University Hospital, à Pusan.L’essai de 4 semaines portant sur 40 patients a été conçu pour tester l’effet de l’ifenprodil...

Continue reading

Algernon erhält in Südkorea Genehmigung der Regulierungsbehörde und Ethikkommission für seine Phase-II-Humanstudie zu Ifenprodil in der Behandlung von COVID-19

VANCOUVER, British Columbia, April 24, 2020 (GLOBE NEWSWIRE) — Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (das „Unternehmen“ oder „Algernon“), ein auf die klinische Entwicklung von Pharmazeutika spezialisiertes Unternehmen, gibt bekannt, dass es die Genehmigung des Ministeriums für Lebensmittel- und Arzneimittelsicherheit in Südkorea sowie die Freigabe der Ethikkommission für eine von einem Prüfarzt geleitete klinische Phase-II-Studie zur Behandlung von COVID-19 mit NP-120 (Ifenprodil) erhalten hat. Das ursprünglich für andere Indikationen entwickelte NP-120 ist ein NMDA-Rezeptor-Antagonist.Leiter der klinischen Prüfung ist Dr. Dong Sik Jung, Professor in der Abteilung für Infektionskrankheiten der Universitätsklinik Dong-A in Busan.Im Rahmen der 4-wöchigen Studie, an der 40 Patienten teilnehmen, soll...

Continue reading

アルジェノン、韓国で実施するCOVID-19治療薬としてのイフェンプロジル第II相臨床試験に規制当局による承認と倫理審査による承認を取得

ブリティッシュコロンビア州バンクーバー発, April 24, 2020 (GLOBE NEWSWIRE) — 臨床病期向け治療薬開発会社のアルジェノン製薬 (Algernon Pharmaceuticals Inc.) (CSE: AGN) (フランクフルト証券取引所: AGW) (OTCQB: AGNPF) (以下、「同社」または「アルジェノン」) は、韓国食品医薬品安全省より、COVID-19治療にリパーパシングされたNMDA受容体拮抗薬NP-120 (イフェンプロジル) の第II相医師主導型臨床試験に対して規制当局による承認と倫理審査による承認を取得したと発表した。釜山の東亜大学病院感染症科教授のジュン・ドン・シク (Dong Sik Jung) 博士が、この試験の責任研究者を務める。患者40名を対象とした4週間の試験は、COVID-19に感染した重症肺炎患者へのイフェンプロジルの薬効を試験すべく設計されている。患者は1:1の比でランダム化され、標準治療 (SOC) またはイフェンプロジル投与によるSOCのいずれかを受ける。主要評価項目は、血中の酸素濃度 (Pa02/Fi02) 測定による肺機能の改善率である。副次的評価項目には、死亡率、機械的換気回数、患者が報告した咳および息切れ (呼吸困難) に対する効果などがある。 第II相臨床試験への登録は、2020年5月8日に開始予定である。「これは、COVID-19患者を対象としたイフェンプロジル初の臨床試験であり、新しい急性肺障害臨床研究プログラムが大きく前進することになります」と、アルジェノンCEOのクリストファー・J・モロー (Christopher J. Moreau) は述べている。「第II相試験で良好なデータが得られれば、イフェンプロジルのCOVID-19治療効果研究継続に重要なマイルストーンとなります。さらに、突発性肺線維症と慢性咳プログラムの推進にもつながります。」同社は、韓国で間近に迫った第II相臨床試験の開始準備をしているが、現時点でNP-120...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.